Brookline Capital Management Initiates Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB)

Research analysts at Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note issued on Thursday,Benzinga reports. The firm set a “buy” rating and a $17.00 price target on the stock. Brookline Capital Management’s target price points to a potential upside of 61.29% from the stock’s current price.

YMAB has been the subject of a number of other reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. BMO Capital Markets cut their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Finally, Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Y-mAbs Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Stock Up 2.3 %

Shares of NASDAQ YMAB opened at $10.54 on Thursday. The firm has a market capitalization of $472.09 million, a P/E ratio of -19.52 and a beta of 0.61. The stock’s 50-day simple moving average is $13.24 and its two-hundred day simple moving average is $12.76. Y-mAbs Therapeutics has a twelve month low of $6.09 and a twelve month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the prior year, the company earned ($0.18) earnings per share. As a group, research analysts anticipate that Y-mAbs Therapeutics will post -0.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the sale, the insider now owns 97,681 shares in the company, valued at approximately $1,315,763.07. This trade represents a 39.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 22.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth approximately $44,000. China Universal Asset Management Co. Ltd. raised its position in shares of Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after acquiring an additional 3,416 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth approximately $133,000. SG Americas Securities LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth approximately $178,000. Finally, Empire Financial Management Company LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth approximately $210,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.